Latest press releases

15-Jul-25

Convatec responds to CMS draft payment proposal for skin substitutes in the United States

25-Apr-25

Convatec receives regulatory approval for ConvaNiox™

11-Apr-25

Convatec welcomes postponement of Local Coverage Determinations (LCDs) on skin substitutes until January 2026

18-Mar-25

Convatec showcases its strongest wound care innovation pipeline ever at EWMA

26-Jan-25

Convatec welcomes the postponement of Local Coverage Determinations (LCDs) on skin substitutes in the United States

10-Oct-24

Convatec update on InnovaMatrix® AC clinical data – second randomised controlled trial authorised

20-Sep-24

Convatec update on InnovaMatrix® AC clinical data

01-May-24

Convatec unveils significant advanced wound care clinical study results

19-Apr-23

Convatec secures a highly innovative technology platform in the anti-infective space

01-Mar-23

FDA clears first placental extracellular matrix medical device for management of second-degree burns

03-Jan-23

Convatec announces the introduction of ConvaFoam™

14-Mar-22

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment1

28-Jan-22

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

22-Nov-21

100 million lives touched as Convatec marks 25 years of AQUACEL®

08-Nov-21

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

21-Jun-21

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS